Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as C21, Compound 21
Buloxibutid · 1 trial · 1 indication
• Absolute change from baseline in FVC (mL) at week 52
| Arm | Type | Description |
|---|---|---|
| Buloxibutid 100 mg BID | EXPERIMENTAL | For 52 weeks. |
| Buloxibutid 50 mg BID | EXPERIMENTAL | For 52 weeks. |
| Placebo BID | PLACEBO_COMPARATOR | For 52 weeks. |
| Name | Type | Description |
|---|---|---|
| Buloxibutid | DRUG | Buloxibutid |
| Placebo | DRUG | Placebo |
Inclusion Criteria 1. Age ≥ 40 years at the time of signing the informed consent. 2. Diagnosed with IPF within 7 years prior to visit 1, as per applicable ATS/ERS/JRS/ALAT guidelines at the time of diagnosis. 3. HRCT scan within 36 months prior to visit 1 with central reading confirming either a or...
Top 15 of 17 competitors
Buloxibutid is an investigational small molecule being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a chronic and progressive lung disease. It is currently in Phase 2 clinical development and has not yet been approved by regulatory authorities. The drug is being studied to evaluate its efficacy and safety in people with IPF.
Buloxibutid targets the angiotensin II type 2 receptor (AT2R). By acting on this receptor, the drug is intended to modulate pathways relevant to fibrosis in Idiopathic Pulmonary Fibrosis. The specific mechanism of action is under investigation in clinical trials.
Buloxibutid is being developed by Vicore Pharma Holding AB, a biopharmaceutical company. The company's American Depositary Shares trade under the ticker symbol VCRE. Vicore Pharma is conducting clinical trials to evaluate the drug's potential in treating Idiopathic Pulmonary Fibrosis.
Buloxibutid is currently in Phase 2 clinical development for Idiopathic Pulmonary Fibrosis. It is an investigational drug and has not received regulatory approval. The drug has been granted Orphan Drug and Fast Track designations by the FDA, reflecting its potential to address an unmet medical need.
Buloxibutid is being evaluated in a Phase 2 clinical trial with the identifier NCT06588686. This randomized, double-blind, placebo-controlled study is assessing the efficacy and safety of the drug in people with Idiopathic Pulmonary Fibrosis. The trial is active but not recruiting, with an enrollment target of 378 participants across multiple countries.
No, Buloxibutid is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for Idiopathic Pulmonary Fibrosis. The FDA has granted it Orphan Drug and Fast Track designations, which are intended to expedite development and review of therapies for serious conditions with unmet needs.